Identification of the Major Circulating Metabolite of Mymd-1 And Elucidation of the Mechanism of Clearance of MYMD-1 in Humans. Role of Aldehyde Oxidase and CYP2A6

MYMD-1 is an immunomodulator that is currently entering Phase II clinical development for the treatment of autoimmune diseases. In preclinical and clinical studies, MYMD-1 has been shown to inhibit the inflammatory cytokines TNF-α, IL-6 and IL-17A1,2. The objectives of the current study were to identify the human circulating metabolites in samples obtained following multiple doses of MYMD-1 and to determine the enzymes involved in their formation.

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Name

This field is for validation purposes and should be left unchanged.

Identification of the Major Circulating Metabolite of Mymd-1 And Elucidation of the Mechanism of Clearance of MYMD-1 in Humans. Role of Aldehyde Oxidase and CYP2A6

Resources to Consider

An Unexpected Major Circulating Metabolite M219 Detected in...